Recipient of federal assistance · SEATTLE, WA

ORLANCE, INC

ORLANCE, INC received $1.3M in federal grants and other assistance in FY2026, on 6 actions, −18% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $10.8M. Its largest awarding agency was National Institutes of Health ($1.3M).

Assistance · FY2026
$1.3M
New awards
0
Actions
6
Since FY2021
$10.8M
UEI
KH6YJYH55G53
Location
SEATTLE, WA
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 2MFY2021
  2. 1MFY2022
  3. 2.2MFY2023
  4. 2.8MFY2024
  5. 1.6MFY2025
  6. 1.3MFY2026

By type

  1. Grants$1.3M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research$1.3M100%

Awarding agencies

  1. National Institutes of Health$1.3M100%
    Department of Health and Human Services

Largest awards

  1. UNIVERSAL INFLUENZA A/B VACCINE$3.3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 25, 2022 – Sep 2, 2026· R44AI153011
  2. CLINIC-READY MACH-1 GENE GUN FOR DELIVERY OF A UNIVERSAL INFLUENZA DNA VACCINE - PROJECT SUMMARY ORLANCE HAS DEVELOPED A LEAD UNIVERSAL…$3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 21, 2023 – Jul 27, 2026· R44AI179440
  3. ENHANCED SEASONAL INFLUENZA VACCINE TARGETING VARIABLE AND CONSERVED ANTIGENS - PROJECT SUMMARY THE CURRENTLY MARKETED SEASONAL INFLUENZA…$1.3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Aug 8, 2024 – Sep 23, 2026· R44AI186932
  4. GENE GUN-DELIVERED RNA VACCINES. - PROJECT SUMMARY COVID-19 LAUNCHED MRNA VACCINES TO THE FOREFRONT AS THE MOST EFFECTIVE AND RAPID…$600K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· May 3, 2024 – Apr 13, 2026· R43AI181303
  5. THERAPEUTIC NUCLEIC ACID VACCINE FOR CHRONIC HEPATITIS B IN HIV/HBV CO-INFECTED INDIVIDUALS - PROJECT SUMMARY OVER 300 MILLION PEOPLE ARE…$598.8K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 11, 2025 – Aug 14, 2026· R41AI195068

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 3, 2026, loaded Oct 3, 2026 · Subawards loaded from FY2021.

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2021–FY2026.